Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer's Drug Aduhelm

THURSDAY, Dec. 29, 2022 -- The U.S. Food and Drug Administration's approval process for the controversial Alzheimer's drug Aduhelm was "rife with irregularities," despite lingering doubts about the power of the pricey medication to slow the disease...